

**ASX ANNOUNCEMENT**

14 May 2026

## Clarity receives \$9.8 million R&D tax incentive refund

**Clarity Pharmaceuticals** (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of \$9,759,467, as part of the Australian Federal Government’s R&D Tax Incentive program. The refund recognises the significant eligible Australian R&D undertaken by Clarity in the radiopharmaceutical field in the financial year ended 30 June 2025.

The Australian Federal Government’s R&D tax incentive program encourages companies to engage and invest in R&D activities by providing a refundable tax offset of up to 48.5% of the eligible activities. The receipt of the \$9.8 million will provide additional funding to further the development of Clarity’s Targeted Copper Theranostic (TCT) platform of products for various cancer indications.

**Clarity’s Executive Chairperson, Dr Alan Taylor, commented,** “We are pleased to receive the RDTI with this significant amount reflecting our commitment to continuous investment into research and development. Clarity is built on a strong foundation of good Australian science, and our team works tirelessly to translate the benchtop research through high-quality clinical development and to the market with the ultimate goal of improving treatment outcomes for people with cancer.

“As we continue growing closer to commercialisation with our SAR-bisPSMA and SARTATE products, generating promising data in late-stage trials, we are appreciative of the non-dilutive funding that extends our cash runway and also enables Clarity to explore novel targets in indications with high unmet needs.”

### About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)

### For more information, please contact:

**Clarity Pharmaceuticals**

Dr Alan Taylor

**Executive Chairperson**[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

Lisa Sadetskaya

**Director, Corporate Communications**[lisa@claritypharm.com](mailto:lisa@claritypharm.com)

*This announcement has been authorised for release by the Executive Chairperson.*

For personal use only